Thieler Law Corp advises investors with losses exceeding $100,000 of the September 25, 2018 lead plaintiff deadline in a class action lawsuit filed against Rockwell Medical Inc (NASDAQ: RMTI) (“Rockwell” or “the Company”). The suit is pending in the U.S. District Court for the Eastern District of New York and investors, who purchased Rockwell Medical Inc securities between March 16, 2018 and June 26, 2018, have until September 25, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Rockwell Medical Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Rockwell was aware that the Centers for Medicare and Medicaid Services (“CMS”) would not pursue Rockwell’s proposal for separate reimbursement for Triferic; Rockwell’s quarterly report for the first quarter of 2018 misstated it reserves; there was a material weakness in Rockwell’s internal controls over financial reporting; consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; Defendant Robert Chioini (“Chioini”), Rockwell’s President and Chief Executive Officer (“CEO”), withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.

On May 10, 2018, the Company revealed that it had “received a letter dated April 24, 2018 from the Securities and Exchange Commission requesting certain information generally with respect to the status of CMS’s determination of separate reimbursement status for Triferic and our current decision not to actively market and sell Triferic without such separate reimbursement.”

On May 22, 2018, the Company revealed that Rockwell’s President and CEO, had been terminated effective immediately. 

On May 23, 2018, NASDAQ revealed that “trading in the company’s stock had been halted today, May 23, 2018, at 09:23:14 Eastern Time for ‘news pending’ at a last sale price of $5.94.”

On May 25, 2018, upon resumption of trading on, the Company’s stock price fell more than 6%, over two consecutive trading days.

On June 27, 2018, the Company revealed that Plante & Moran PLLC, the company’s public auditor, , resigned its position with the Company over Rockwell’s pursuit of separate reimbursement status for Triferic.

Following this news, NASDAQ: RMTI fell over 16%, over two consecutive trading days.

If you were negatively impacted by your investment in Rockwell Medical Inc securities between March 16, 2018 and June 26, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185